<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320228</url>
  </required_header>
  <id_info>
    <org_study_id>B274</org_study_id>
    <nct_id>NCT01320228</nct_id>
  </id_info>
  <brief_title>Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor</brief_title>
  <acronym>ORLIFAT</acronym>
  <official_title>Effect of Dietary Components on Gastrointestinal Side Effects Induced by Orlistat, a Lipase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the Orlifat trial is to investigate if dietary fibres from linseeds and
      dairy calcium (Capolac ®) may reduce gastrointestinal side effects related to increased fecal
      fat content, induced by treatment with Alli® (orlistat). Secondly, effect on food intake,
      anthropometry, Quality of Life and cardiovascular risk markers will be evaluated. The trial
      is designed as a randomised 2 x 2 factorial 13-weeks parallel intervention, in which 72 obese
      participants will be randomised to supplementation with flaxseed fibres and/or dairy calcium
      concentrate (Capolac) in addition to treatment with Alli ®:

        1. Alli® (60 mg t.i.d) plus placebo (rice flour)

        2. Alli® plus 5 g flaxseed fibers

        3. Alli® plus 1200 mg Ca from Capolac

        4. Alli® plus 5 g flaxseed fibers and 1200 mg Ca from Capolac
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratings of gastrointestinal comfort</measure>
    <time_frame>baseline, week 0, 2, 4, 8, 12</time_frame>
    <description>Subjective assessment of gastrointestinal comfort using visual analogue scales</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total fecal fat excretion</measure>
    <time_frame>week 0 and 4</time_frame>
    <description>Average total fecal fat excreted during five days in week 0 and week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total, LDL and HDL cholesterol</measure>
    <time_frame>baseline and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratings of quality of life</measure>
    <time_frame>baseline, week 0, 2, 4, 8 and 12</time_frame>
    <description>Questionnaire used to assess quality of life related to obesity and treatment thereof</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>baseline, week 0, 2, 4, 6, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist and hip circumference</measure>
    <time_frame>Baseline, week 0, 2, 4, 6, 8, 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>food intake</measure>
    <time_frame>week 0 and 4</time_frame>
    <description>Intake of total fat and energi estimated using 7d weighed food records</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Habitual intake of dietary fiber and calcium</measure>
    <time_frame>baseline</time_frame>
    <description>Habitual intake of dietary fiber and calcium estimated using food frequency questionnaires</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Alli treatment plus placebo (rice flour)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flax fiber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capolac+Flax fiber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Alli treatment plus placebo (rice flour)</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Capolac</intervention_name>
    <description>Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)</description>
    <arm_group_label>Capolac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flax fiber</intervention_name>
    <description>Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)</description>
    <arm_group_label>Flax fiber</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Capolac+Flax fiber</intervention_name>
    <description>Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)</description>
    <arm_group_label>Capolac+Flax fiber</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-60 years of age

          -  men and women

          -  BMI 30-40 kg/m2

        Exclusion Criteria:

          -  Dairy allergy and/or intolerance, allergy to Orlistat

          -  Infectious and metabolic diseases

          -  Gastrointestinal diseases (previous and current)

          -  Troubles swallowing tablets and capsules

          -  Dietary supplement use during the trial and 1 month prior to the trial

          -  Postmenopausal (selfreported)

          -  Pregnancy and lactation

          -  Treatment with oral anticoagulation medications, ciclosporin, levothyroxin,
             antiepileptika, acarbose and amiodaron

          -  Prescription medication will be considered on an individual basis at the screening
             visit according to SOP

          -  Dieting or other changes of diet within 3 months

          -  Participation in other trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arne Astrup, MD, Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen</name>
      <address>
        <city>Frederiksberg C</city>
        <zip>1958</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>September 1, 2014</last_update_submitted>
  <last_update_submitted_qc>September 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Arne Astrup</investigator_full_name>
    <investigator_title>Professer, Dr. Med.</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>orlistat</keyword>
  <keyword>fat excretion</keyword>
  <keyword>fiber</keyword>
  <keyword>dairy calcium</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

